The Medicines and Healthcare products Regulatory Agency (MHRA) has initiated a UK-wide consultation aimed at redefining the regulatory framework surrounding gene therapies. This move is designed to align regulations with the rapid advancements in scientific research and technological innovations within the field. The consultation seeks to gather insights from industry stakeholders, including regulatory professionals, quality assurance experts, and those involved in chemistry, manufacturing, and controls.
As gene therapies continue to evolve, the current definitions may no longer adequately encompass the complexities and nuances of new treatment modalities. By engaging with the industry, the MHRA aims to ensure that the regulatory environment remains robust and responsive, facilitating the safe and effective delivery of these groundbreaking therapies. The implications of this consultation could be significant, potentially reshaping the landscape for gene therapy development and commercialization in the UK.
Open the full market picture for your next decision →
